<DOC>
	<DOCNO>NCT00171743</DOCNO>
	<brief_summary>The purpose study determine whether switch tacrolimus cyclosporine microemulsion benefit post-transplant diabetes management ( term glycogenic control insulin dosage ) stable liver transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety Cyclosporine Microemulsion Diabetic Adult Stable Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>At least 4 month posttransplant Patients treatment tacrolimus Posttransplant diabetes treated insulin least one month Exclusion Criteria Known hypersensitivity cyclosporine microemulsion Investigational drug within 60 day baseline study Patients comply study requirement Other protocoldefined exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adults</keyword>
	<keyword>Post transplant diabetes</keyword>
</DOC>